Quality-of-life considerations in patients with advanced lung cancer: Effect of topotecan on symptom palliation and quality of life

Oncologist

Volumn 9, Issue SUPPL. 6, 2004, Pages 14-24

  Gralla, Richard J ^a  

^a New York Lung Cancer Alliance   (United States)

Author keywords

Non small cell lung carcinoma; Oral administration; Palliative therapy; Quality of life; Small cell lung carcinoma; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; TOPOTECAN;

HUMAN; LUNG TUMOR; PALLIATIVE THERAPY; PATHOLOGY; QUALITY OF LIFE; REVIEW; SMALL CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; HUMANS; LUNG NEOPLASMS; PALLIATIVE CARE; QUALITY OF LIFE; TOPOTECAN;

EID: 16644396074     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.9-90006-14     Document Type: Review

References (78)

1. Ardizzoni A, Tjan-Heijnen VC, Postmus PE et al. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase HI Trial-08923. J Clin Oncol 2002;20:3947-3955.
2. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
3. Albain KS, Crowley JJ, Hutchins L et al. Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base. Cancer 1993;72:1184-1191.
4. von Pawel J, Schiller JH, Shepherd FA et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667.
5. Kvale PA, Simoff M, Prakash UB. Palliative care. Chest 2003;123(suppl 1):284S-311S.
6. Griffin JP, Nelson JE, Koch KA et al. End-of-life care in patients with lung cancer. Chest 2003;123(suppl 1):312S-331S.
7. Weiss SC, Emanuel LL, Fairclough DL et al. Understanding the experience of pain in terminally ill patients. Lancet 2001;357:1311-1315.
8. Zhukovsky DS, Gorowski E, Hausdorff J et al. Unmet analgesic needs in cancer patients. J Pain Symptom Manage 1995;10:113-119.
9. Di Maio M, Gridelli C, Gallo C et al. Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. Br J Cancer 2004;90:2288-2296.
10. Benedetti C, Brock C, Cleeland C et al. NCCN practice guidelines for cancer pain. Oncology (Huntingt) 2000:14:135-150.
11. Socinski MA, Morris DE, Masters GA et al. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003;123(suppl 1):226S-243S.
12. Osoba D, Murray N, Gelmon K et al. Quality of life, appetite, and weight change in patients receiving dose-intensive chemotherapy. Oncology (Huntingt) 1994;8:61-65; discussion 65-66, 69.
13. Ruckdeschel JC, Piantadosi S. Quality of life in lung cancer surgical adjuvant trials. Chest 1994;106(suppl 6):324S-328S.
14. Cella D. The Functional Assessment of Cancer Therapy-Lung and Lung Cancer Subscale assess quality of life and meaningful symptom improvement in lung cancer. Semin Oncol 2004;31(suppl 9):ll-15.
15. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-2067.
16. Hollen PJ, Gralla RJ, Cox C et al. A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer. Lung Cancer 1997;18:119-136.
17. Splinter TAW. Response rate as criterium to evaluate chemotherapy in non-small cell lung cancer. Lung Cancer 1991:7:91-104.
18. Klastersky J, Sculier JP, Lacroix H et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990;8:1556-1562.
19. Markman M. Why does a higher response rate to chemotherapy correlate poorly with improved survival? J Cancer Res Clin Oncol 1993;119:700-701.
20. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-613.
21. Buyse M, Thirion P, Carlson RW et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000;356:373-378.
22. Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003;21:1404-1411.
23. Chassany O, Sagnier P, Marquis P et al. Patient-reported outcomes: the example of health-related quality of life-a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 2002;36:209-238.
24. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
25. Hollen PJ, Gralla RJ, Kris MG et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 1994;73:2087-2098.
26. Cella DF, Bonomi AE, Lloyd SR et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-220.
27. Sneeuw KC, Aaronson NK. Sprangers MA et al. Evaluating the quality of life of cancer patients: assessments by patients, significant others, physicians and nurses. Br J Cancer 1999:81:87-94.
28. Stephens RJ, Hopwood P, Girling DJ et al. Randomized trials with quality of life endpoints: are doctors' ratings of patients' physical symptoms interchangeable with patients' self-ratings? Qual Life Res 1997;6:225-236.
29. Plunkett TA, Chrystal KF, Harper PG. Quality of life and the treatment of advanced lung cancer. Clin Lung Cancer 2003;5:28-32.
30. Smith EL, Hann DM, Ahles TA et al. Dyspnea, anxiety, body consciousness, and quality of life in patients with lung cancer. J Pain Symptom Manage 2001;21:323-329.
31. Dudgeon DJ, Lertzman M. Dyspnea in the advanced cancer patient. J Pain Symptom Manage 1998;16:212-219.
32. Langendijk JA, Aaronson NK, de Jong JM et al. Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. J Clin Oncol 2001;19:2123-2133.
33. Jassem J, Krzakowski M, Roszkowski K et al. A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life. Lung Cancer 2002;35:73-79.
34. Ellis PA, Smith IE, Hardy JR et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995;71:366-370.
35. Cullen MH, Joshi R, Chetiyawardana AD et al. Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer 1988:58:359-361.
36. Osoba D, Rusthoven JJ, Turnbull KA et al. Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer. J Clin Oncol 1985;3:1478-1485.
37. Tummarello D, Graziano F, Isidori P et al. Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C. Cancer Chemother Pharmacol 1995;35:249-253.
38. Fernandez C, Rosell R, Abad-Esteve A et al. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol 1989;28:29-33.
39. Hardy JR, Noble T, Smith IE. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br j Cancer 1989:60:764-766.
40. Cesano A, Lane SR, Ross GA et al. Stabilization of disease as an indicator of clinical benefit associated with chemotherapy in non-small-cell lung cancer patients. Int j Oncol 20O0;17:587-590.
41. Pujol IL, Daures IP, Riviere A et al. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001;93:300-308.
42. Sundstrom S, Bremnes RM, Kaasa S et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002;20:4665-4672.
43. Naughton MI, Herndon IE 2nd, Shumaker SA et al. The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033. Qual Life Res 2002; 11:235-248.
44. Schiller JH, Adak S, Cella D et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:2114-2122.
45. Heyes A. Clinical trial experience with Functional Assessment of Cancer Therapy-Lung in conventional and targeted non-small cell lung cancer therapy. Semin Oncol 2004;31(suppl 9):16-22.
46. Laack E, Dickgreber N, Muller T et al. Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 2004;22:2348-2356.
47. Ardizzoni A, Hansen H, Dombernowsky P et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. I Clin Oncol 1997:15:2090-2096.
48. Eckardt I, Gralla R, Palmer MC et al. Topotecan (T) as second-line therapy in patients (Pts) with small cell lung cancer (SCLC): a phase II study. Ann Oncol 1996;7(suppl 5):107.
49. TM) in relapsed small cell lung cancer (SCLC). A multicentre phase II study. Lung Cancer 1997;18(suppl 1):35.
50. von Pawel J, Gatzemeier U, Pujol JL et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 2001;19:1743-1749.
51. Eckardt JR. Emerging role of weekly topotecan in recurrent small-cell lung cancer. The Oncologist 2004:9(suppl 6):25-32.
52. Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer: a review of literature from 1970 to 1995. Chest 1998:113:467-481.
53. Morita S, Kobayashi K, Eguchi K et al. Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model. Jpn J Clin Oncol 2003;33:470-476.
54. Buccheri GF, Ferrigno D, Tamburini M et al. The patient's perception of his own quality of life might have an adjunctive prognostic significance in lung cancer. Lung Cancer 1995:12:45-58.
55. Finkelstein DM, Cassileth BR, Bonomi PD et al. A pilot study of the Functional Living Index-Cancer (FLIC) Scale for the assessment of quality of life for metastatic lung cancer patients. An Eastern Cooperative Oncology Group study. Am I Clin Oncol 1988:11:630-633.
56. Treat J, Huang CH, Lane SR et al. Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status. The Oncologist 2004;9:173-181.
57. Levin J, Lilenbaum RC, Masters GA et al. Association of topotecan with improved performance status (PS) in relapsed small cell lung cancer (SCLC) patients with poor PS at baseline. Proc Am Soc Clin Oncol 2004;22:7208.
58. Coates A, Abraham S, Kaye SB et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-208.
59. Griffin AM, Butow PN, Coates AS et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996;7:189-195.
60. Carelle N, Piotto E, Bellanger A et al. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002:95:155-163.
61. Liu G, Franssen E, Fitch MI et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997:15:110-115.
62. Claessen KA, de Vries JT, Huisman SJ et al. Long-term venous access with a Hickman catheter: complications and patient satisfaction. Neth J Surg 1990;42:47-49.
63. Greco FA. Evolving role of oral chemotherapy for the treatment of patients with neoplasms. Oncology (Huntingt) 1998;12(suppl 4):43-50.
64. Navarro RP, Morrow T, Baran R. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy. Manag Care Interface 2002;15:55-62.
65. Kollmannsberger C, Mross K, Jakob A et al. Topotecan-a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 1999;56:1-12.
66. van Warmerdam LJ, Verweij J, Schellens JH et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 1995;35:237-245.
67. Schellens JH, Creemers GJ, Beijnen JH et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 1996;73:1268-1271.
68. Kuhn J, Rizzo J, Eckardt J et al. Phase I bioavailability study of oral topotecan. Proc Am Soc Clin Oncol 1995;14:474.
69. Herben VM, Rosing H, ten Bokkel Huinink WW et al. Oral topotecan: bioavailability and effect of food co-administration. Br J Cancer 1999;80:1380-1386.
70. Burris HA 3rd. The evolving role of oral topotecan. Semin Hematol 1999;36(suppl 8):26-32.
71. White SC, Cheeseman S, Anderson H et al. A phase II study of oral topotecan in advanced non-small cell lung cancer: useful symptom palliation and 10 month median survival. Proc Am Soc Clin Oncol 1999;18:527a.
72. Eckardt JR. Feasibility of oral topotecan plus intravenous paclitaxel in advanced non-small-cell lung cancer. Oncology 2001;61(suppl l):30-34.
73. Eckardt J, Palmer M, Fanucchi M et al. Oral topotecan (OT) as single-agent first-line treatment for patients with extensive disease (ED) small cell lung cancer (SCLC) ineligible for standard therapy: a phase II study. Proc Am Soc Clin Oncol 2000;19:494a.
74. Eckardt JR. Feasibility of oral topotecan in previously untreated patients with small-cell lung cancer ineligible for standard therapy. Oncology 2001;61(suppl l):42-46.
75. Jett JR, Bernath AM Jr, Hillman SL et al. Oral topotecan and paclitaxel with G-CSF support in patients with untreated extensive stage small cell (ED-SCLC): a phase II trial of the NCCTG. Proc Am Soc Clin Oncol 2002;21:326a.
76. Eckardt JR, von Pawel J, Hainsworth JD et al. Single agent oral topotecan (PO) versus intravenous (IV) topotecan in patients (pts) with chemosensitive small cell lung cancer (SCLC). An international phase III study. Proc Am Soc Clin Oncol 2003;22:619.
77. Gralla RJ, Eckardt J, von Pawel J et al. Quality of life with single agent oral topotecan vs intravenous topotecan in patients with chemosensitive small cell lung cancer (SCLC). An international phase III study. Lung Cancer 2003;41(suppl 2):20.
78. Gralla RJ, Eckardt J, Grotzinger KM. Quality of life (QoL) with single agent oral topotecan vs intravenous topotecan in patients with chemosensitive small cell lung cancer (SCLC). QoL in balance. Lung Cancer 2003;41(suppl 2):237.